GSK hands 2 of its less profitable vaccines to Bavarian Nordic

The deal, worth about $335 million upfront, will help GSK simplify its supply chain and allow it to reinvest in higher growth areas, according to the company.

By Jacob Bell • Oct. 21, 2019

Merck to lay off 500 US-based commercial employees

Affected employees will depart on Jan. 3, 2020, said the drugmaker, which claimed the cuts are not part of a new restructuring. 

By Andrew Dunn • Oct. 18, 2019

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Merck's Ebola vaccine wins key European vote

Erevebo has already been administered to 274,000 people, and data indicate it is effective against the virus currently causing an African outbreak.

By Jonathan Gardner • Oct. 18, 2019

Sanofi investing in gene therapy as R&D focus turns toward rare disease

R&D chief John Reed told BioPharma Dive Sanofi is retrofitting a vaccine facility in France to produce the viral vectors needed to deliver gene therapies.

By Andrew Dunn • Oct. 17, 2019

Lilly cancer drug pipeline hit by trial setback

Pegilodecakin, an immunotherapy acquired in the pharma's $1.6 billion deal for Armo BioSciences, failed to extend survival in patients with pancreatic cancer. 

By Ned Pagliarulo • Oct. 16, 2019

Give up board chairmanship? No thanks, US big pharma CEOs say

Pfizer CEO Albert Bourla will soon head the pharma's board, too, adding another example of a large drugmaker with unified leadership.

By Jonathan Gardner • Oct. 16, 2019

Lilly shuttering UK neuroscience research site

Most employees will be relocated to a new facility in the area, although Lilly expects to lay off as many as 80 workers.

By Jonathan Gardner • Oct. 15, 2019

Pelosi drug plan would save $370B, but could reduce R&D, forecasters say

Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according to the CBO.

By Jonathan Gardner • Oct. 14, 2019

Lilly's 1-drug migraine business gets support with new approval

An OK for Reyvow, an acute migraine drug, complements Lilly's preventive therapy Emgality and could strengthen the company's footing in an increasingly crowded market.

By Ned Pagliarulo • Oct. 11, 2019

J&J hit with $8B jury verdict over Risperdal as legal troubles mount

The multi-billion dollar payment stems from claims J&J illegally marketed its blockbuster antipsychotic, which was linked to lasting side effects.

By Andrew Dunn • Oct. 9, 2019

Eylea casts a shadow over Novartis' latest approval

At least one analyst sees few reasons for doctors to use Novartis' Beovu in place of the Regeneron eye drug, citing a less-than-ideal label.

By Jacob Bell • Oct. 8, 2019

J&J paying $20M to settle Ohio opioid suits

The pharma giant joins Endo, Mallinckrodt and Allergan in reaching a settlement deal with Cuyahoga and Summit counties in Ohio.

By Ned Pagliarulo • Oct. 2, 2019

Novartis, Microsoft ink 5-year AI alliance

Personalizing eye disease treatment and improving CAR-T manufacturing are first on an agenda the companies hope will better prove AI's utility in medicine.

By Ned Pagliarulo • Oct. 2, 2019

Sanofi's story needs to be 'better told,' new CEO says

Paul Hudson, who took over from Olivier Brandicourt as company chief a month ago, is preparing to lay out his strategy for the French drugmaker.

By Ned Pagliarulo • Oct. 1, 2019

Novartis, Lilly drugs set new survival bar in breast cancer

Study results detailing the survival benefit to Kisqali and Verzenio could help persuade more doctors to prescribe the targeted drugs. 

By Ned Pagliarulo • Sept. 29, 2019

AstraZeneca, Merck strengthen lead in PARP drug class

AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.

By Jonathan Gardner • Sept. 28, 2019

Pfizer's Read to step down as chairman, handing role to CEO Bourla

Albert Bourla took over as CEO in January. Now, the company veteran will also replace Read as head of the pharma giant's board of directors.

By Andrew Dunn • Sept. 27, 2019

Pfizer's new JAK drug works, but class safety concerns linger

While effective, the class has come under regulatory scrutiny for increasing patients' risk of blood clots and cardiovascular events.

By Jacob Bell • Sept. 27, 2019

Novartis recall of generic Zantac expands to US

British drugmaker GlaxoSmithKline, meanwhile, said it would halt distribution of Zantac product in countries where it sells the heartburn drug.

By Kristin Jensen • Sept. 26, 2019

GSK to spend $120M on new manufacturing hub for drug pipeline

The investment is part of nearly $400 million the British pharma has spent since 2017 to build out its vaccine and specialty drug production in the U.S.

By Kristin Jensen • Sept. 26, 2019

Merck, Pfizer execs explain how they tap sites for cancer trials

The decisions hinge on a trial's phase and tumor type but are also affected by certain medical experts and the companies' history with a site.

By Jacob Bell • Sept. 23, 2019

Does disclosure of pharma payments harm patient trust in doctors?

A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.

By Andrew Dunn • Sept. 23, 2019

Is the future of diabetes treatment better drugs or better care?

Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.

By Jonathan Gardner • Sept. 23, 2019

Facing $4B in claims, Insys doubts ability to pay out via Chapter 11

The bankrupt opioid drugmaker disclosed it does not expect to be able to meet "by a wide margin" the more than 8,000 outstanding claims against it.

By Andrew Dunn • Sept. 20, 2019

The top drugs facing cuts under Pelosi's pricing plan

Democrats' plan would put pressure on top-sellers from Bristol-Myers Squibb, Regeneron and Merck & Co, among others.

By Jonathan Gardner • Sept. 20, 2019